(firstQuint)Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke.

 The investigators hypothesis focuses on the effect of riboflavin given for the first three hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration.

 This administration would produce a reduction of excitotoxic damage and consequently generate clinical improvement, while a lower income and a better functional outcome of patients at three months.

.

 Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke@highlight

Administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic stroke to know if it causes a reduction of glutamate-mediated excitotoxicity.

